{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"116"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"121"}],"units":"Participants"}],"description":"An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product, was also an adverse event. The number of participants who experienced ≥1 AE was reported per protocol for the first course of treatment.","groups":[{"description":"Participants receive pembrolizumab 200 mg IV Q3W for up to 35 treatments (approximately 2 years).","id":"OG000","title":"Pembrolizumab 200 mg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All allocated participants who received at least 1 dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to approximately 59 months","title":"Number of Participants Who Experienced an Adverse Event (AE)","type":"SECONDARY","unitOfMeasure":"Participants"}